|
Clinical data
|
No. of Case (%)
|
MMP-11 level
|
P -value
|
|---|
| | |
Mean ± SD (ng/ml)
| |
|---|
|
NO. of patients
|
86
| | |
|
Gender
| | | |
|
Male
|
60(69.8%)
|
45.76 ± 22.89
|
0.200
|
|
Female
|
26(30.2%)
|
38.79 ± 23.17
| |
|
Age (yrs)
| | | |
|
Median
|
51(50-56)
| | |
|
<65
|
63(73.3%)
|
43.40 ± 22.76
|
0.166
|
|
≥65
|
23(26.7%)
|
50.79 ± 21.96
| |
|
Differentiation
| | | |
|
G1, G2
|
23(26.7%)
|
48.56 ± 23.30
|
0.235
|
|
G3
|
63(73.3%)
|
41.86 ± 22.90
| |
|
Histology
| | | |
|
Intestinal type adenocarcinoma
|
54(62.8%)
|
44.22 ± 23.92
| |
|
Mucinous carcinoma
|
20(23.2%)
|
45.89 ± 17.99
|
0.527
|
|
Signet-ring cell carcinoma
|
12(14.0%)
|
53.44 ± 23.80
| |
|
ECOG
| | | |
|
0-1
|
68(79.1%)
|
46.14 ± 21.40
|
0.610
|
|
2
|
18(20.9%)
|
43.33 ± 26.49
| |
|
Disease stage
| | | |
|
III c
|
26(30.2%)
|
43.22 ± 31.02
|
0.288
|
|
IV
|
60(69.8%)
|
48.45 ± 23.57
| |
|
Metastasis site
| | | |
|
Lymph node
|
35(40.7%) *#
|
52.55 ± 24.72
| |
|
Peritoneum
|
21(24.4%) #
|
33.44 ± 14.46
|
0.006 (*0.029, #0.002)
|
|
Internal organs
|
30(34.9%) *
|
40.42 ± 22.74
| |
|
Chemotherapy cycles
|
377
| | |
|
Median
|
6.00(3.00-12.00)
| | |
|
mTTP (m)
| | | |
|
Median
|
6.00(5.29-6.71)
| | |
|
mOS (m)
| | | |
|
Median
|
10.00(8.51-11.50)
| | |
|
Response
| | | |
|
PR
|
38(44.2% )
|
46.85 ± 24.92
|
0.182
|
|
SD
|
22(25.6% )
|
37.34 ± 19.95
| |
|
PD
|
26(30.2% )
|
48.97 ± 20.23
| |
- Abbreviations: PR, partial response; SD, stable disease; PD, progression of disease. Analysis of the difference between groups using analysis of variance (ANOVA). Where differences were identified, further analysis (between pairs of groups, with respective pairs for each molecule marked with *and *) was performed using Scheffe (95% confidence interval (CI))
